Pzena Investment Management LLC Acquires 191,289 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Pzena Investment Management LLC raised its stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 24.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 976,633 shares of the company's stock after buying an additional 191,289 shares during the quarter. Pzena Investment Management LLC owned 5.13% of USANA Health Sciences worth $44,183,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in USANA Health Sciences in the fourth quarter valued at about $66,000. CWM LLC raised its position in shares of USANA Health Sciences by 49.6% during the fourth quarter. CWM LLC now owns 1,267 shares of the company's stock worth $68,000 after purchasing an additional 420 shares during the period. BOKF NA raised its position in shares of USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company's stock worth $133,000 after purchasing an additional 2,031 shares during the period. Trexquant Investment LP acquired a new stake in shares of USANA Health Sciences during the fourth quarter worth about $266,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock worth $284,000 after purchasing an additional 494 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences Stock Performance

USANA Health Sciences stock traded up $0.12 during midday trading on Wednesday, reaching $39.54. The stock had a trading volume of 44,275 shares, compared to its average volume of 78,755. The firm's fifty day simple moving average is $42.49 and its 200-day simple moving average is $45.32. USANA Health Sciences, Inc. has a 1-year low of $37.35 and a 1-year high of $64.39. The stock has a market capitalization of $753.24 million, a P/E ratio of 12.28, a price-to-earnings-growth ratio of 1.36 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The firm had revenue of $212.87 million during the quarter, compared to analyst estimates of $218.64 million. During the same period in the prior year, the business posted $0.89 EPS. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, major shareholder Myron W. Wentz sold 3,700 shares of the firm's stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $48.61, for a total value of $179,857.00. Following the completion of the transaction, the insider now directly owns 7,880,043 shares in the company, valued at $383,048,890.23. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Myron W. Wentz sold 3,700 shares of USANA Health Sciences stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $48.61, for a total value of $179,857.00. Following the transaction, the insider now owns 7,880,043 shares of the company's stock, valued at $383,048,890.23. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,338 shares of company stock valued at $1,204,486. 0.33% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on USNA. StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, July 24th. DA Davidson dropped their price target on USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating on the stock in a research report on Thursday, July 25th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.